Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

Golimumab Achieved Primary and Major Secondary Endpoints in the Largest

Phase 3 Biologic Trial Completed to Date in Psoriatic Arthritis

BOSTON, Nov. 7 /PRNewswire/ -- Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest Phase 3 biologic study ever completed in subjects with psoriatic arthritis. Findings presented at the American College of Rheumatology (ACR) Annual Scientific Meeting showed that at week 14 of the 405-patient study in subjects with active psoriatic arthritis, 51 percent of patients receiving golimumab 50 mg and 45 percent of patients receiving golimumab 100 mg experienced at least 20 percent improvement in arthritis signs and symptoms (ACR 20) compared with 9 percent of patients receiving placebo (P < 0.001 for both comparisons). Golimumab-treated patients maintained significant improvements in arthritis through week 24 and also showed substantial and sustained improvements in skin and nail psoriatic disease (as measured by a 75 percent reduction in Psoriasis Area and Severity Index [PASI 75] in patients with baseline body surface area with psoriasis of at least three percent, and the Nail Psoriasis Severity Index [NAPSI]).

Golimumab, Centocor Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF- alpha biologic therapy. With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as a monthly SC injection and an every twelve-week intravenous (IV) infusion (approximately 30-minutes) therapy.

"The availability of treatments that target TNF-alpha have dramatically changed rheumatologists' ap
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  With a vision to ... medications, a Global Pharmaceutical and Biotech manufacturer selects ... and turnkey solution to protect their animal health ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... serialized and aggregated by the Xyntek and Antares ...
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
(Date:10/22/2014)... Va. and AUSTIN, Texas ... Inc. and PureMHC LLC today announced they have ... develop novel antibody-based immunotherapies designed to target cancers. ... of phosphorylated peptides displayed on the surfaces of ... phosphopeptide tumor targets (PTTs), derived from proteins that ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... Calif., Aug. 19 Burton Medical, Inc., the leader ... Burton LE-35  to deliver superior illumination, improved reach, and ...  The 35-watt LE-35 provides two to five times more ... improving efficacy and visibility.  This task light provides illuminance ...
... Md., Aug. 19 Novavax, Inc. (Nasdaq: NVAX ... press briefing by U.S. Health and Human Services Secretary Kathleen ... plan to accelerate the development of drugs and vaccines to ... statement of support for the plan,s five key initiatives: ...
Cached Medicine Technology:NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 2NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 3
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... there are only 24 hours in a day, that doesn’t seem ... time within their busy schedules for exercise and fitness. Fortunately, one ... get in shape. Here are five ways you can reach your ... Up Your Commute , Consider riding a bike or taking the ... daily routine. If you must use your car to get to ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Akeso ... solutions for the treatment of bacterial infections, microbial biofilms, ... has joined its board of directors. , ... Engineering Systems at The Massachusetts Institute of Technology, or ... faculty since 1968. Dr. Sinskey also holds positions as ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
(Date:10/22/2014)... 2014 (HealthDay News) -- Measures taken by Firestone officials ... Liberia may have limited the spread of the disease ... The Firestone Natural Rubber Co. provides health services to ... nearby densely populated communities. Between Aug. 1 and ... cases among those 80,000 people. That incidence rate of ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... -- The best states for smokers trying to kick ... least quit-friendly states are Georgia and Louisiana, according to ... Association report examines quit-smoking programs and treatments offered in ... smokers with easy access to smoking cessation counseling and ...
... remain in their homes as public funding for long-term care ... a new study by the UCLA Center for Health Policy ... Should as much as $100 million in additional cuts ... as proposed by the state Legislature, seniors with disabilities will ...
... dread gaining weight during the holiday season, but there may ... to reach for yet another helping of holiday goodies. ... Journal of Obesity , mastering simple mindful ... dieting. Women in the study who experienced the greatest ...
... (UCM) have compared internet use and frequency in Spain with ... that Spanish women use the internet less frequently and the ... than average. Juan Martn Fernandez, researcher at the Complutense ... published in the Reis journal, states that "Spanish ...
... still a one in eight lifetime risk that a woman ... disease remains early detection. Now, Women & infants Hospital of ... next level with the installation of the most advanced imaging ... is the first and only facility in southeastern New England ...
... -- A group of chimpanzees at a research site frequently ... widely regarded as a defining characteristic of human behavior. ... first started sharing, according to study author Jill Pruetz, a ... her colleagues observed chimpanzees at the Fongoli research site in ...
Cached Medicine News:Health News:Some States Make Stopping Smoking Easier Than Others 2Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 2Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 4Health News:Stress reduction and mindful eating curb weight gain among overweight women 2Health News:Stress reduction and mindful eating curb weight gain among overweight women 3Health News:Spain's digital gender gap is larger than European average 2Health News:Hospital gives first tomosynthesis mammograms in region this week 2Health News:Chimps Shed Light on How Humans Learned to Share 2
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
... Evolis™ is a self contained microplate ... based EIA assays. The system is dedicated ... encountered in todays busy laboratory. The system ... of EIA assays that satisfy their microplate ...
Medicine Products: